Alinidine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Alinidine
Alinidine.png
Systematic (IUPAC) name
N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine
Clinical data
Legal status Uncontrolled
Identifiers
CAS number 33178-86-8 N
ATC code None
PubChem CID 36354
ChemSpider 33429 YesY
UNII E7IDJ8DS1D YesY
ChEMBL CHEMBL278581 YesY
Chemical data
Formula C12H13Cl2N3 
Mol. mass 270.16 g/mol
 N (what is this?)  (verify)

Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.[2]

Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.[3]

References[edit]

  1. ^ Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflugers Arch 1987, 410:83-91
  2. ^ Current Opinion in Pharmacology 2007, 7:208–213
  3. ^ Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.". J Am Coll Cardiol 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.